CompletedNot Applicable

Breast Cancer Diet Intervention Study

80 participantsStarted 2009-06-12

Plain-language summary

The investigators have already proven that Mitotic Activity Index (MAI)is the most robust measure of proliferation in breast cancer tissue. The purpose was to study whether 18 and 2-4 hours pre-operative per-oral carbohydrate loading (often given in gastrointestinal surgery i.e. enhanced recovery after surgery=ERAS) influences proliferation in the tumor, serum insulin characteristics, metabolic profile and survival.

Who can participate

Age range25 Years – 100 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Non-operable patients (i.e" patients with T3-4 (\>5 cm) disease or distant metastases at the time of operation).
✕. All patients who refuse to participate.
✕. All patients with DCIS, micro-invasive cancer \< 2mm diameter or tumors with histologic poor-quality material.
✕. Co-morbidity (Insulin dependent Diabetes Mellitus, Cushing syndrome, previous or concurrent cancers except CIN and non-melanomatous skin cancer.
✕. Mental inability to participate.
✕. Persons allergic to one of the compounds in any of the two diets.

What they're measuring

Mitotic Activity Index (MAI)

Timeframe: Trough completion of surgery of all included patients, an average of 1,5 years

Trial details

NCT IDNCT03886389

SponsorHelse Stavanger HF

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2017-07-07

View on ClinicalTrials.gov More Early-stage Breast Cancer trials